Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme J. Moyle

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
The Journal of Infectious Diseases|February 18, 2005
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infectionGraeme J Moyle, Adrian Wildfire, Sundhiya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 22, 2005
Efficacy of selected treatments of HIV wasting: a systematic review and meta-analysisGraeme J Moyle, Karen Schoelles, Kyle Fahrbach, et al.
The Journal of Pain|September 18, 2022
A Comparison of Self-reported Pain Measures Between Sensory Phenotypes in HIV-associated Sensory NeuropathyHarriet I Kemp, Jan Vollert, Nicholas W S Davies, et al.
HIV Clinical Trials|August 30, 2008
Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormoneDerek C Macallan, Christine Baldwin, Sundihya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapyGraeme J Moyle, Eric S Daar, Joseph M Gertner, et al.
Plos One|February 7, 2015
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsGraeme J Moyle, Chloe Orkin, Martin Fisher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2005
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination StudyGraeme J Moyle, Edwin DeJesus, Pedro Cahn, et al.
Antiviral Therapy|December 15, 2010
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive menPaul A Randell, Akil G Jackson, Marta Boffito, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2009
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individualsMartin Fisher, Graeme J Moyle, Mohsen Shahmanesh, et al.
AIDS (London, England)|September 15, 2004
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimenMarta Boffito, Michael Kurowski, Guido Kruse, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
The Journal of Infectious Diseases|February 18, 2005
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infectionGraeme J Moyle, Adrian Wildfire, Sundhiya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 22, 2005
Efficacy of selected treatments of HIV wasting: a systematic review and meta-analysisGraeme J Moyle, Karen Schoelles, Kyle Fahrbach, et al.
The Journal of Pain|September 18, 2022
A Comparison of Self-reported Pain Measures Between Sensory Phenotypes in HIV-associated Sensory NeuropathyHarriet I Kemp, Jan Vollert, Nicholas W S Davies, et al.
HIV Clinical Trials|August 30, 2008
Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormoneDerek C Macallan, Christine Baldwin, Sundihya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapyGraeme J Moyle, Eric S Daar, Joseph M Gertner, et al.
Plos One|February 7, 2015
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsGraeme J Moyle, Chloe Orkin, Martin Fisher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2005
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination StudyGraeme J Moyle, Edwin DeJesus, Pedro Cahn, et al.
Antiviral Therapy|December 15, 2010
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive menPaul A Randell, Akil G Jackson, Marta Boffito, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 30, 2009
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individualsMartin Fisher, Graeme J Moyle, Mohsen Shahmanesh, et al.
AIDS (London, England)|September 15, 2004
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimenMarta Boffito, Michael Kurowski, Guido Kruse, et al.
Pageof 3